Bo Pharm and Baitu Life Sciences announce the establishment of a joint AI pipeline research and development company.

On June 15, Hemebio and Biotopharmaceuticals announced a comprehensive strategic partnership to jointly establish a new AI pipeline R&D company MegaStream Techbio targeting the global market. Hemebio will provide MegaStream with access to its fully human antibody platform, target biology expertise, and global clinical development capabilities; while Biotopharmaceuticals will offer underlying AI technology empowerment, model engineering support, and intelligent R&D capabilities. The initial pipeline of MegaStream will consist of both existing AI drug development projects and newly initiated AI-native pipeline R&D projects cooperated by both parties. The founders of the two companies will be entitled to potential upfront payments, success milestones, and equity sharing as per industry practices.